Please assess the completion status of the following clinical trial:

Trial Title: Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic diagnosis of primary or de novo MDS using WHO classification~* Non-del(5q) low or Intermediate-1risk MDS~* ECOG performance status of 0-1~* Documented significant cytopenia for at least 2 months~* Must have discontinued growth factors (EPO, G-CSF, GM-CSF) for at least 21 days prior to study entry~* All study participants must be registered into the mandatory RevAssist® program and be willing and able to comply with the requirements of RevAssist®~* Females of childbearing potential should have two negative serum pregnancy tests with a sensitivity of at least 50 mIU/mL. The first test should be performed within 10-14 days, and the second test within 24 hours of prescribing lenalidomide (prescriptions must be filled within seven days)~Exclusion Criteria:~* Known hypersensitivity to Telintra™ (intravenous or oral)~* Known prior therapy with or hypersensitivity to thalidomide or lenalidomide~* Prior allogenic bone marrow transplant for MDS~* History or prior malignancy~  * Except for treated carcinoma of uterine cervix, basal cell or squamous cell skin cancer, or other cancers (e.g. breast, prostate) for which patient has been disease-free for at least 3 years.~* MDS evolving from:~  * A pre-existing myeloproliferative disorder~ * An autoimmune disease~ * Secondary to prior treatment with radiation or chemotherapy~* History of MDS IPSS score\>1.0~* Pregnant or lactating women~* Leptomeningeal or leukemic meningitis~* Prior treatment with DNA methyltransferase inhibitors (DMTI) \[e.g., azacitadine, decitabine, etc.\]

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Revlimid® in Combination with Telintra ® (Type: EXPERIMENTAL): Lenalidomide (Revlimid®) followed by Telintra® until MDS progression or lack of efficacy.

Based on this trial design, predict the completion outcome and termination type (if applicable).